18+ · Research use only
Semaglutide 15mg, Philippines
Peptide studied in Phase 3 human trials. Lyophilized powder, stocked in Metro Manila. For laboratory research use only.
What it did in trials
- 14.9% avg weight loss, Phase 3
- Fewer cardiovascular events, Phase 3
Choose a pack
Pack price replaces the 10% off. One compound per pack.
Pack price replaces the standing 10% off; they don't stack. One compound per pack.
Check out once for the whole cart. Pay by QR, confirm on WhatsApp.
Add more compounds if you like, then check out once. You pay by QR on your order page and send the screenshot on WhatsApp.
In the Philippines
GCash · Maya · QR Ph bank transfer · InstaPay
From abroad
- International transfer
Wise · International bank transfer · Zelle · Crypto
Payment details are sent in the WhatsApp chat once your order is confirmed.
Order by 12 noon on a weekday for same-day Metro Manila
Includes water, syringes, pads · plain box
60-day money-back guaranteeTerms
Order by 12 noon on a weekday for same-day delivery in Metro Manila
Metro Manila rider ₱150 · Luzon 1-2 days · Visayas 2-3 days · Mindanao 3-5 days
Everything to reconstitute is included
5 x 3ml water · 50 syringes · 50 pads · plain outer packaging
60-day money-back guarantee
If an accredited independent laboratory reports that this vial is not the compound on the label, we refund what you paid for it. Evidence within 60 calendar days of delivery; you do not send anything back. Terms
Updated 12 October 2026
- Human evidence
- Phase 3
- Manufacturing
- cGMP · ISO 9001 · ISO 13485
- Latest batch report
- Report pending
- Storage
- 2 to 8 °C sealed
Semaglutide in the Philippines
Semaglutide is a GLP-1 receptor agonist and the single-target reference point for the whole incretin class. Where tirzepatide adds GIP activity and retatrutide adds glucagon on top of that, semaglutide acts at GLP-1 alone, which is why it is the comparator arm in most of the trial literature the newer compounds are measured against. In STEP 1 (Wilding et al., NEJM 2021) it produced a mean 14.9% body weight reduction over 68 weeks at the 2.4mg weekly dose. SELECT (Lincoff et al., NEJM 2023) went on to study cardiovascular outcomes in participants with established cardiovascular disease and without diabetes. It carries the longest and most extensively published record of the three.
Primara Labs stocks semaglutide as a 15mg lyophilized vial, held in cold storage inside Metro Manila. Because inventory is already in the country there is no international shipping leg, no customs exposure and no multi-week wait. Verified orders placed before noon dispatch the same day across Metro Manila, with courier delivery reaches Luzon in 1 to 2 business days, the Visayas in 2 to 3 and Mindanao in 3 to 5.
Semaglutide acts at one receptor, GLP-1, and is the single-target reference point for the incretin class. Tirzepatide adds GIP, and retatrutide adds GIP and glucagon, a three-receptor design still in Phase 3 and approved nowhere, where semaglutide under its brand names is an approved medicine in many markets. Both are held in the same Metro Manila cold storage for buyers who buy retatrutide Philippines stock alongside this vial.
The 15mg semaglutide vial is a powder until it is reconstituted, and it keeps best cold, between 2 and 8°C, with the cap on and out of sunlight. Ordering is done in a WhatsApp chat rather than a checkout. Start it from this page, the vial is already named in the message, and we reply with availability and the peso total. Delivery is same-day Metro Manila delivery before 12 noon, and 1 to 5 business days by region elsewhere. Background on the molecule sits in the Semaglutide guide.
Deeper read: Tirzepatide vs semaglutide in the Philippines
Regulatory status
Semaglutide. FDA Philippines: not established. US FDA: Approved for glycemic control in type 2 diabetes mellitus and related cardiovascular and kidney risk reduction (Ozempic, Rybelsus); chronic weight management and cardiovascular risk reduction in obesity or overweight (Wegovy). Checked 23 September 2026.
Sold for laboratory research only, not for human consumption. Primara Labs does not give medical advice or dosing guidance. Regulatory Status Tracker
Laboratory handling
Reconstitution reference
| BAC water added | Resulting concentration | Note |
|---|---|---|
| 1.0 ml | 15 mg/ml | Highest concentration, smallest volumes |
| 2.0 ml | 7.5 mg/ml | Common reference dilution |
| 3.0 ml | 5 mg/ml | Larger volumes, finer graduation |
Reconstitute with bacteriostatic water. Reference values are for laboratory preparation only. Other volumes: reconstitution calculator, prefilled for Semaglutide 15mg.
Handling and storage
Sealed vials
Store sealed lyophilised vials refrigerated at 2 to 8 °C, away from light.
Primara Labs storage instructionAdding diluent
Add the diluent slowly down the inside wall of the vial rather than straight onto the powder.
Mixing
The US prescribing instructions for tesamorelin, a lyophilised peptide medicine, tell users to swirl the vial to mix the powder and liquid, and not to shake it.
Tesamorelin US instructions for use, DailyMed · checked 23 September 2026Appearance
The same instructions say not to use the solution if it is cloudy, discoloured or has particles in it.
Tesamorelin US instructions for use, DailyMed · checked 23 September 2026After the stopper is punctured
CDC guidance, citing USP chapter 797, is that a multi-dose vial once opened is dated and discarded within 28 days unless the manufacturer states another date, and never used past its original expiry.
CDC, Preventing Unsafe Injection Practices · checked 23 September 2026What it did in trials
Sources for the trial highlights
- 1.STEP 1, 2021. Adults with BMI of 30 or greater (27 or greater with at least one weight-related coexisting condition), without diabetes.
- 2.SELECT, 2023. Patients 45 years or older with preexisting cardiovascular disease and BMI of 27 or greater, no history of diabetes.
Benefits studied
Body-weight reduction
Phase 3 humanIn STEP 1, a phase 3 trial in adults with BMI of 30 or greater (27 or greater with at least one weight-related coexisting condition), without diabetes (n=1,961), mean body weight fell 14.9% on the 2.4 mg arm over 68 weeks, against 2.4% lost on placebo (treatment-policy estimand).
Wilding JPH et al. N Engl J Med 2021;384:989-1002 · checked 23 September 2026Cardiovascular events
Phase 3 humanIn SELECT, a phase 3 trial in patients 45 years or older with preexisting cardiovascular disease and BMI of 27 or greater, no history of diabetes (n=17,604), the primary endpoint, death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke, occurred in 6.5% on semaglutide against 8.0% on placebo, a hazard ratio of 0.80 (95% CI 0.72 to 0.90).
Lincoff AM et al. N Engl J Med 2023 (SELECT) · checked 23 September 2026Body-weight reduction with type 2 diabetes
Phase 3 humanIn STEP 2, a phase 3 trial in adults with BMI of at least 27 kg/m2 and HbA1c 7-10% (53-86 mmol/mol), diagnosed with type 2 diabetes at least 180 days before screening (n=1,210), mean body weight fell 9.6% on the 2.4 mg arm over 68 weeks, against 3.4% lost on placebo.
Davies M et al. Lancet 2021 (STEP 2) · checked 23 September 2026Two-year weight reduction
Phase 3 humanIn STEP 5, a phase 3 trial in adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes (n=304), mean body weight fell 15.2% on the 2.4 mg arm over 104 weeks, against 2.6% lost on placebo (treatment-policy estimand).
Garvey WT et al. Nat Med 2022 (STEP 5) · checked 23 September 2026Maintenance of weight reduction
Phase 3 humanIn STEP 4, a phase 3 withdrawal trial (n=803), participants who continued semaglutide after a 20-week run-in lost a further 7.9% by week 68, while those switched to placebo regained 6.9%.
Rubino D et al. JAMA 2021 (STEP 4) · checked 23 September 2026
Side effects reported
In STEP 3, discontinuation because of adverse events was 5.9% on 2.4 mg, against 2.9% on placebo. The most frequently reported adverse events were gastrointestinal adverse events in 82.8% on 2.4 mg against 63.2% on placebo, nausea in 58.2% on 2.4 mg against 22.1% on placebo, constipation in 36.9% on 2.4 mg against 24.5% on placebo and diarrhoea in 36.1% on 2.4 mg against 22.1% on placebo.
Wadden TA et al. JAMA 2021 (STEP 3) · checked 23 September 2026In SELECT, discontinuation because of adverse events was 16.6% on semaglutide 2.4 mg, against 8.2% on placebo.
Lincoff AM et al. N Engl J Med 2023 (SELECT) · checked 23 September 2026In STEP 8, discontinuation because of adverse events was 3.2% on semaglutide 2.4 mg and 12.6% on liraglutide 3.0 mg, against 3.5% on placebo (pooled). The most frequently reported adverse events were gastrointestinal disorders in 84.1% on semaglutide 2.4 mg and 82.7% on liraglutide 3.0 mg against 55.3% on placebo (pooled), nausea in 61.1% on semaglutide 2.4 mg and 59.1% on liraglutide 3.0 mg against 22.4% on placebo (pooled), constipation in 38.9% on semaglutide 2.4 mg and 31.5% on liraglutide 3.0 mg against 23.5% on placebo (pooled) and diarrhoea in 27.8% on semaglutide 2.4 mg and 18.1% on liraglutide 3.0 mg against 25.9% on placebo (pooled).
Rubino DM et al. JAMA 2022 (STEP 8) · checked 23 September 2026Findings are described as the research reported them, with the level of evidence for each. They are not a claim about any vial sold here, which is supplied for laboratory research use only.
How it works
Semaglutide is a GLP-1 analogue that selectively binds to and activates the GLP-1 receptor, the target of native GLP-1.
Targets: GLP-1 receptor
What the research shows
Semaglutide at 2.4 mg has seven completed phase 3 trials in the Research Desk dataset: STEP 1 to STEP 5, STEP 8 and SELECT, published between 2021 and 2023. SELECT studied cardiovascular outcomes in people with cardiovascular disease and overweight or obesity without diabetes. Its wider trial record is larger than this dataset holds.
Phase 3 · 68 weeks
STEP 1In STEP 1, a phase 3 trial of semaglutide in adults with BMI of 30 or greater (27 or greater with at least one weight-related coexisting condition), without diabetes (n=1,961), mean body weight fell 14.9% on 2.4 mg over 68 weeks, against 2.4% on placebo (treatment-policy estimand; Wilding JPH et al. N Engl J Med 2021;384:989-1002).
STEP 1: Discontinuation for adverse events is not given in the abstract; discontinuation for gastrointestinal adverse events was 4.5% against 0.8% on placebo.
Phase 3 · 68 weeks
STEP 2In STEP 2, a phase 3 trial of semaglutide in adults with BMI of at least 27 kg/m2 and HbA1c 7-10% (53-86 mmol/mol), diagnosed with type 2 diabetes at least 180 days before screening (n=1,210), mean body weight fell 9.6% on 2.4 mg over 68 weeks, against 3.4% on placebo (Davies M et al. Lancet 2021 (STEP 2)).
The most frequently reported adverse events were gastrointestinal adverse events in 63.5% on 2.4 mg and 57.5% on 1.0 mg against 34.3% on placebo.
Phase 3 · 68 weeks
STEP 3In STEP 3, a phase 3 trial of semaglutide in US adults without diabetes with overweight (BMI 27 or greater) plus at least 1 comorbidity or obesity (BMI 30 or greater) (n=611), mean body weight fell 16.0% on 2.4 mg over 68 weeks, against 5.7% on placebo (treatment-policy estimand; Wadden TA et al. JAMA 2021 (STEP 3)).
In STEP 3, discontinuation because of adverse events was 5.9% on 2.4 mg, against 2.9% on placebo. The most frequently reported adverse events were gastrointestinal adverse events in 82.8% on 2.4 mg against 63.2% on placebo, nausea in 58.2% on 2.4 mg against 22.1% on placebo, constipation in 36.9% on 2.4 mg against 24.5% on placebo and diarrhoea in 36.1% on 2.4 mg against 22.1% on placebo.
Phase 3 · 68 weeks
STEP 4In STEP 4, a phase 3 trial of semaglutide in adults with BMI of at least 30 (or 27 or greater with at least 1 weight-related comorbidity) without diabetes, who reached the 2.4 mg maintenance dose during a 20-week run-in (n=803), mean body weight changed by -7.9% on continued 2.4 mg, weeks 20 to 68 over 68 weeks, against +6.9% on switched to placebo (treatment-policy estimand; Rubino D et al. JAMA 2021 (STEP 4)).
In STEP 4, discontinuation because of adverse events was 2.4% on continued 2.4 mg, weeks 20 to 68, against 2.2% on switched to placebo. The most frequently reported adverse events were gastrointestinal adverse events in 41.9% on continued 2.4 mg, weeks 20 to 68 against 26.1% on switched to placebo, diarrhoea in 14.4% on continued 2.4 mg, weeks 20 to 68 against 7.1% on switched to placebo, nausea in 14.0% on continued 2.4 mg, weeks 20 to 68 against 4.9% on switched to placebo and constipation in 11.6% on continued 2.4 mg, weeks 20 to 68 against 6.3% on switched to placebo.
Phase 3 · 104 weeks
STEP 5In STEP 5, a phase 3 trial of semaglutide in adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes (n=304), mean body weight fell 15.2% on 2.4 mg over 104 weeks, against 2.6% on placebo (treatment-policy estimand; Garvey WT et al. Nat Med 2022 (STEP 5)).
In STEP 5, discontinuation because of adverse events was 5.9% on 2.4 mg, against 4.6% on placebo. The most frequently reported adverse events were gastrointestinal adverse events in 82.2% on 2.4 mg against 53.9% on placebo, nausea in 53.3% on 2.4 mg against 21.7% on placebo, diarrhoea in 34.9% on 2.4 mg against 23.7% on placebo and constipation in 30.9% on 2.4 mg against 11.2% on placebo.
Phase 3b · 68 weeks
STEP 8In STEP 8, a phase 3b trial of semaglutide in US adults with BMI of 30 or greater, or 27 or greater with 1 or more weight-related comorbidities, without diabetes (n=338), mean body weight fell 15.8% on semaglutide 2.4 mg and 6.4% on liraglutide 3.0 mg over 68 weeks, against 1.9% on placebo (pooled) (treatment-policy estimand; Rubino DM et al. JAMA 2022 (STEP 8)).
In STEP 8, discontinuation because of adverse events was 3.2% on semaglutide 2.4 mg and 12.6% on liraglutide 3.0 mg, against 3.5% on placebo (pooled). The most frequently reported adverse events were gastrointestinal disorders in 84.1% on semaglutide 2.4 mg and 82.7% on liraglutide 3.0 mg against 55.3% on placebo (pooled), nausea in 61.1% on semaglutide 2.4 mg and 59.1% on liraglutide 3.0 mg against 22.4% on placebo (pooled), constipation in 38.9% on semaglutide 2.4 mg and 31.5% on liraglutide 3.0 mg against 23.5% on placebo (pooled) and diarrhoea in 27.8% on semaglutide 2.4 mg and 18.1% on liraglutide 3.0 mg against 25.9% on placebo (pooled).
The first published batch report is retatrutide 20mg batch RETA-4728-A, Janoshik-tested for bacterial endotoxin (key H2KI86I8GWB4), at primaralabs.com/coa. Reports for further compounds are published there per batch as they are issued.
- Type
- GLP-1 analogue
- Molecular formula
- C187H291N45O59
- Molecular weight
- 4,114 g/mol
- CAS
- 910463-68-2
- PubChem
- CID 56843331
- Presentation
- Lyophilized powder, 15 mg / vial
- Vial size
- 15mg
- Catalogue code
- PRM-018
Frequently asked
Semaglutide questions, answered
How much is Semaglutide in the Philippines?
At Primara Labs, Semaglutide 15mg is ₱1,990 for a single vial, ₱1,547 per vial in a 5 pack (₱7,735 total) and ₱1,216 per vial in a 10 pack (₱12,160 total). Prices are in pesos and the pack price is shown on the product page before you order.
Where can I buy Semaglutide in the Philippines?
Primara Labs keeps Semaglutide 15mg in stock in Metro Manila cold storage. Order on WhatsApp from the product page: the message is typed for you, and stock, the total and delivery are confirmed in the chat. There is no on-site checkout.
Do you deliver Semaglutide to Cebu, Davao and the provinces?
Yes. Metro Manila: same day before 12 noon, Grab Express / Lalamove, ₱150; Luzon: 1 to 2 business days, J&T Express, ₱250; Visayas: 2 to 3 business days, J&T Express, ₱250; Mindanao: 3 to 5 business days, J&T Express, ₱300. Cebu is in the Visayas and Davao in Mindanao. Courier is free on orders over ₱10,000 anywhere in the Philippines. Below that, a Metro Manila rider is ₱150, J&T Express is ₱250 to Luzon and the Visayas and ₱300 to Mindanao.
Is Semaglutide FDA approved in the Philippines?
Semaglutide. FDA Philippines: not established. US FDA: Approved for glycemic control in type 2 diabetes mellitus and related cardiovascular and kidney risk reduction (Ozempic, Rybelsus); chronic weight management and cardiovascular risk reduction in obesity or overweight (Wegovy). Checked 23 September 2026. Primara Labs supplies it for research use only; it is not for human consumption.
Is semaglutide in stock and how fast is delivery?
Semaglutide 15mg is in stock. Verified orders placed before noon dispatch the same day across Metro Manila. Provincial orders ship by courier and reach Luzon in 1 to 2 business days, the Visayas in 2 to 3 and Mindanao in 3 to 5.
How does semaglutide in a vial differ from the pharmacy product?
They are different categories. The pharmacy product is a finished, prescription-only preparation supplied in a pen at a fixed concentration. What is sold here is lyophilized powder in a vial, supplied for laboratory research use only, with no prescription and no clinical support attached.
How is semaglutide reconstituted for research use?
The lyophilized powder is reconstituted with bacteriostatic water. Adding 2.0 ml to a 15mg vial yields a 7.5 mg/ml reference concentration, and 1.0 ml yields 15 mg/ml. Reconstituted material should be refrigerated and used within 28 days.
How does semaglutide compare with tirzepatide and retatrutide?
By receptor targets. Semaglutide acts at GLP-1 only, tirzepatide at GLP-1 and GIP, retatrutide at GLP-1, GIP and glucagon. Semaglutide and tirzepatide are stocked here as 15mg vials and retatrutide as a 20mg vial, so compare them per milligram rather than per vial.
How do I order semaglutide from Primara Labs?
Ordering runs through WhatsApp. Tap the order button on this page and the chat opens with your vial pre-filled. Confirm quantity and delivery details in the conversation and payment instructions follow there.
What is Semaglutide studied for?
Semaglutide at 2.4 mg has seven completed phase 3 trials in the Research Desk dataset: STEP 1 to STEP 5, STEP 8 and SELECT, published between 2021 and 2023. SELECT studied cardiovascular outcomes in people with cardiovascular disease and overweight or obesity without diabetes. Its wider trial record is larger than this dataset holds.
What side effects were reported for Semaglutide?
In STEP 3, discontinuation because of adverse events was 5.9% on 2.4 mg, against 2.9% on placebo. The most frequently reported adverse events were gastrointestinal adverse events in 82.8% on 2.4 mg against 63.2% on placebo, nausea in 58.2% on 2.4 mg against 22.1% on placebo, constipation in 36.9% on 2.4 mg against 24.5% on placebo and diarrhoea in 36.1% on 2.4 mg against 22.1% on placebo. In SELECT, discontinuation because of adverse events was 16.6% on semaglutide 2.4 mg, against 8.2% on placebo. In STEP 8, discontinuation because of adverse events was 3.2% on semaglutide 2.4 mg and 12.6% on liraglutide 3.0 mg, against 3.5% on placebo (pooled). The most frequently reported adverse events were gastrointestinal disorders in 84.1% on semaglutide 2.4 mg and 82.7% on liraglutide 3.0 mg against 55.3% on placebo (pooled), nausea in 61.1% on semaglutide 2.4 mg and 59.1% on liraglutide 3.0 mg against 22.4% on placebo (pooled), constipation in 38.9% on semaglutide 2.4 mg and 31.5% on liraglutide 3.0 mg against 23.5% on placebo (pooled) and diarrhoea in 27.8% on semaglutide 2.4 mg and 18.1% on liraglutide 3.0 mg against 25.9% on placebo (pooled).
How should Semaglutide be stored?
Store sealed lyophilised vials refrigerated at 2 to 8 °C, away from light. CDC guidance, citing USP chapter 797, is that a multi-dose vial once opened is dated and discarded within 28 days unless the manufacturer states another date, and never used past its original expiry.
Does Primara Labs publish lab reports for Semaglutide?
The first published batch report is retatrutide 20mg batch RETA-4728-A, Janoshik-tested for bacterial endotoxin (key H2KI86I8GWB4), at primaralabs.com/coa. Reports for further compounds are published there per batch as they are issued.
Related compounds
Answers
Questions about Semaglutide, answered
All compounds supplied by Primara Labs are for laboratory research use only and are not for human consumption, diagnostic or therapeutic use. Statements on this page describe published research and have not been evaluated by the Philippine FDA. See Research Use Only terms.